Xilis has established a 3D patient-derived ex-vivo organoid technology that preserves the tumor microenvironment including the immune cell populations. Our technology platform called MicroOrganoSphere ("MOS"), couples a proprietary, patented automated instrument that reproducibly generates millions of organoids with comprehensive functional assays and AI-powered analytics to provide data and insights into drug efficacy, therapeutic utility and patient selection/clinical trial design. Our platform is applicable for evaluating all therapeutic modalities, including IO and cellular therapy. We have deployed our platform in both solid tumors and hematological cancers, including NSCLC, breast, colorectal cancer and multiple myeloma.